Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report (Second Report) ...

The FTC's first report drew a strong response from the PBM sector, with lawsuits filed in both directions. The FTC has accused the big three of operating a "perverse drug rebate system," while the ...

FTC’s report focused on three largest PBMs ... A transformation in the PBM space will likely lead to fairer pricing and improved access to essential medications for customers, ultimately ...

T he Federal Trade Commission (FTC) released a 60-page report Tuesday targeting the three biggest pharmacy benefit managers (PBMs), claiming the companies hiked the prices of specialty drugs by ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

The Federal Trade Commission on Jan. 14 published a second interim staff report on the prescription drug middleman industry, ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs.